Chr. Hansen revenue up in third quarter
Commodity prices affected Health & Nutrition unit results
Global bioscience company Chr. Hansen reported revenue of EUR249.8 million (US$276.8 million) in the third quarter of 2015-16, compared with EUR228.1 in same period a year ago.
“We experienced modest growth in Health & Nutrition, as the animal health business was negatively impacted by commodity prices for milk and meat remaining at extraordinarily low levels,” said CEO Cees de Jong. “Despite the current pressure on the agricultural sector, the long-term growth prospects for our animal health business remain very positive.”
In January, the company acquired Nutritional Physiology Co. (NPC) in an effort to further broaden its microbial platform and expand its presence into the beef cattle segment.
“During the past three months, we have made good progress with integrating NPC, launched a second product for plant health with good first sales, and, within the human microbiome area, successfully completed a clinical study showing a positive physiological effect of the bacteria tested,” de Jong said. “Based on the results achieved, we have moved to the next stage in our clinical development plan. Finally, it is very encouraging to see a strong performance by our bioprotective solutions for dairy and other food categories.”
The company’s outlook for 2015-16 is unchanged from April 7.